NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Vu

Appreciate your thoughts

So sometime between Aug

The Company currently continues to anticipate reporting topline trial data in September, and anticipates providing further updates as the process progresses.

https://nwbio.com/nw-bio-announces-completion-of-further-data-gathering-for-phase-iii-trial/

and

October 5th -

https://nwbio.com/northwest-biotherapeutics-announces-data-lock-of-phase-iii-trial/

somebody had a cup of coffee with somebody

and decided that the journal route was the only way to go?

Avisol Capital Partner - (seeking alpha - 20th) is thinking along your lines -

FWIW

When can we see the data?
According to one reference, NWBO is taking a lot of time to analyse the data because, due to the long age of the trial, a lot of new developments have taken place in GBM science that has to be accounted for. For example, it's been discovered in the last few years that wild-type IDH is oncogenic, while mutant IDH genes have better prognosis in early stage gliomas, which, although they are relatively rare in glioblastoma, about 10%, is probably having to be factored into the NWBO data. These things are delaying the analysis. Several slots were booked in major conferences but later cancelled by the company. They also may publish the data in a journal first.

Thanks for both your posts

regards